John Libbey Eurotext

Journal de Pharmacie Clinique

MENU

Anti-interleukin 6 (tocilizumab) in rheumatoid arthritis Volume 32, issue 2, Juin 2013

Figures

See all figures

Authors
Service de rhumatologie, Centre hospitalier universitaire Ibn Rochd, Faculté de médecine et de pharmacie de Casablanca, Maroc

Interleukin-6 is an important inflammatory cytokine in rheumatoid arthritis (RA). Its therapeutic targeting is done with a humanized antibody directed against its receptor or tocilizumab. This therapeutic agent is administered every 4 weeks. It has been an important therapeutic development in Japan and internationally, to show its effectiveness in combination with methotrexate (MTX) in active RA with an inadequate response to conventional therapy including MTX or anti-TNF, and as monotherapy in patients with intolerance or inefficacy of MTX. This efficiency is exerted on the clinical, biological and radiological. Its safety profile is as good with most common side effects of upper respiratory infection, a moderate elevation of transaminases and total cholesterol, without documented consequences on cardiovascular risk. This review summarizes the efficacy data, the reported results of different studies, and adverse events. It is difficult to place TCZ and many other new drugs in the algorithm treatment at present.